Breaking the Crosstalk of the Cellular Tumorigenic Network by Low-Dose Combination Therapy in Lung Cancer Patient-Derived Xenografts

By
Justin.choi
-
0
20
Selecting drug combinations for overcoming resistances, NSCLC patient-derived xenograft tumors were treated with a low dose combination of cabozantinib, afatinib, plerixafor and etoricoxib.
[Communications Biology]

Sorry, but the selected Zotpress account can't be found.

Full Article